At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VVOS Vivos Therapeutics
Pre-Mkt 11-05 08:03:10 EST
0.1112
+0.0014
+1.28%
盘前0.1111
-0.0001-0.09%
07:42 EST
High0.1153Low0.1097Vol338.22K
Open0.1153D1 Closing0.1098Amplitude5.10%
Mkt Cap3.74MTradable Cap3.62MTotal Shares33.61M
T/O37.94KT/O Rate1.04%Tradable Shares32.59M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vivos Therapeutics Regains Compliance with NASDAQ Shareholders' Equity Requirement
Reuters  ·  10-21
Vivos Therapeutics Regains Compliance with NASDAQ Shareholders' Equity Requirement
Vivos Therapeutics Reports NASDAQ Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
THOMSON REUTERS  ·  10-21
Vivos Therapeutics Reports NASDAQ Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
Vivos Therapeutics Acquires Stake in SOD Sciences IP
TIPRANKS  ·  10-20
Vivos Therapeutics Acquires Stake in SOD Sciences IP
Vivos Therapeutics Closes Acquisition of Stake in Sod Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More than 325,000 New Patients Through the Aha Channel
THOMSON REUTERS  ·  10-20
Vivos Therapeutics Closes Acquisition of Stake in Sod Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More than 325,000 New Patients Through the Aha Channel
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
GlobeNewswire  ·  10-20
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Vivos Therapeutics Acquires 11% Stake in SOD Sciences
Reuters  ·  10-20
Vivos Therapeutics Acquires 11% Stake in SOD Sciences
Vivos Therapeutics Agrees to Acquire 11% Stake in SOD Sciences
Reuters  ·  10-15
Vivos Therapeutics Agrees to Acquire 11% Stake in SOD Sciences
Vivos Therapeutics - to Buy 11% Fully Diluted Equity Interest in Sod Sciences
THOMSON REUTERS  ·  10-15
Vivos Therapeutics - to Buy 11% Fully Diluted Equity Interest in Sod Sciences
Vivos Therapeutics - Closing Expected on or About October 15, 2026, Subject to Conditions
THOMSON REUTERS  ·  10-15
Vivos Therapeutics - Closing Expected on or About October 15, 2026, Subject to Conditions
Vivos Therapeutics - to Buy 50% Co-Ownership in Sod Pseudohypoxia Test for $12 Mln in Series C Preferred Stock
THOMSON REUTERS  ·  10-15
Vivos Therapeutics - to Buy 50% Co-Ownership in Sod Pseudohypoxia Test for $12 Mln in Series C Preferred Stock
Vivos Therapeutics Agrees to Acquire Minority Stake in Sod Sciences and 50% Interest in Proprietary Pseudohypoxia Test
THOMSON REUTERS  ·  10-15
Vivos Therapeutics Agrees to Acquire Minority Stake in Sod Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Vivos Therapeutics - no Cash Consideration Payable Under Agreement
THOMSON REUTERS  ·  10-15
Vivos Therapeutics - no Cash Consideration Payable Under Agreement
Press Release: Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Dow Jones  ·  10-15
Press Release: Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Vivos Therapeutics - Dismisses Baker Tilly US, Llp as Independent Auditor Effective Sept 29, 2026 - SEC Filing
THOMSON REUTERS  ·  10-01
Vivos Therapeutics - Dismisses Baker Tilly US, Llp as Independent Auditor Effective Sept 29, 2026 - SEC Filing
Vivos Therapeutics - Audit Reports for Fy2025 and Fy2024 Include Substantial Doubt About Going Concern - SEC Filing
THOMSON REUTERS  ·  10-01
Vivos Therapeutics - Audit Reports for Fy2025 and Fy2024 Include Substantial Doubt About Going Concern - SEC Filing
Vivos Therapeutics Dismisses Baker Tilly, Names Haynie as New Auditor
Reuters  ·  10-01
Vivos Therapeutics Dismisses Baker Tilly, Names Haynie as New Auditor
Vivos Therapeutics reports progress in material cost reductions, revenue growth
TIPRANKS  ·  09-29
Vivos Therapeutics reports progress in material cost reductions, revenue growth
Vivos Therapeutics Launches Restructuring Plan Targeting $3.6 Million in Annual Savings Starting Q4 2026
Reuters  ·  09-29
Vivos Therapeutics Launches Restructuring Plan Targeting $3.6 Million in Annual Savings Starting Q4 2026
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
THOMSON REUTERS  ·  09-29
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Therapeutics - Primary Savings from Staff Reductions, Vendor Changes, and Contract Savings
THOMSON REUTERS  ·  09-29
Vivos Therapeutics - Primary Savings from Staff Reductions, Vendor Changes, and Contract Savings
No data available

Introduction

Company Name.
Vivos Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
Issue price:
--